Re: O'Brien-Fleming spendinf function
I believe that Padzur can't help but be aware of the data being achieved in the trials being run by UCLA, but they won't be a part of the regulatory filing. I believe that this is true of all the regulators who'll be considering the vaccine. By itself it more than doubles the odds of living to 5 years with GBM. If you add one or more of the products tested with it at UCLA the odds of living 5 years increase by roughly 1000%, ten times what's achieved by the SOC.
They'll approve the vaccine based on more than doubling the SOC, but they'll all know that results will be far better with off label use of other approved therapeutics added to the protocol. Remember, these other therapeutics don't provide such benefit unless used in combination with DCVax-L.